Lights, camera, Alexion! Fresh off an FDA approval for Ultomiris in NMOSD, AstraZeneca’s rare disease unit has put out a film sharing patient stories.
AstraZeneca’s rare disease arm Alexion is debuting an original short film Thursday for patients with the rare neurological condition neuromyelitis optica spectrum disorder (NMOSD).
LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for...
MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024. In this role, Ms. Heim will lead the Canadian affiliate in its unwavering commitment to helping people affected by rare diseases live longer, healthier lives.
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
FDA expands AZ`s Ultomiris to NMOSD after prior rejection
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
Alexion Pharma`s Biologic Soliris (eculizumab) Receives Approval in the U.S.
Alexion Pharma`s Biologic Ultomiris (ravulizumab) Receives Approval in the U.S.
Pfizer has handed off an AAV capsid aimed at a rare neurological disease target to AstraZeneca’s rare disease arm Alexion as part of a larger, previously announced bundle deal.